Cervical Cancer: Open Access
Open Access

HPV vaccination; cervical cancer; prevention; global incidence; human papillomavirus; public health; vaccine efficacy; health equity

Introduction

Cervical cancer ranks as the fourth most common cancer among women globally, with approximately 604,000 new cases and 342,000 deaths reported in 2020 by the World Health Organization (WHO). The disease disproportionately affects women in low-resource settings, where access to screening and treatment is limited. Nearly all cases of cervical cancer are attributable to infection with oncogenic strains of HPV, a sexually transmitted virus with over 200 identified genotypes, of which HPV-16 and HPV-18 are responsible for about 70% of cases [1]. The development of HPV vaccines—such as Gardasil, Cervarix, and Gardasil 9—has marked a pivotal shift in the fight against this preventable cancer. These vaccines target the most prevalent high-risk HPV strains, offering a proactive strategy to interrupt the infection-to-cancer pathway. Since their introduction in 2006, HPV vaccines have been integrated into national immunization programs in over 100 countries, yet their global impact varies widely due to differences in uptake and healthcare infrastructure. This article aims to evaluate the effectiveness of HPV vaccination in preventing cervical cancer and its contribution to reducing global incidence, while exploring the barriers that hinder its universal success [2].

Methods

To assess the role of HPV vaccination, this article synthesizes data from peer-reviewed studies, clinical trials, and public health reports published between 2006 and 2025. Key sources include randomized controlled trials (RCTs) evaluating vaccine efficacy, such as the FUTURE I/II trials for Gardasil and the PATRICIA trial for Cervarix, alongside longitudinal cohort studies tracking cervical cancer incidence in vaccinated populations. Global incidence data were drawn from the WHO, the International Agency for Research on Cancer (IARC), and national cancer registries. The analysis also incorporates programmatic data from countries with high vaccination coverage (e.g., Australia, Sweden) and contrasts these with regions of low coverage (e.g., sub-Saharan Africa, South Asia) [3]. Vaccine efficacy was measured in terms of protection against HPV infection, precancerous cervical lesions (CIN2/3), and invasive cervical cancer. Additional considerations included vaccination schedules (two- or three-dose regimens), target populations (primarily preadolescent girls, with some programs including boys), and herd immunity effects. Qualitative insights on barriers to vaccination were derived from public health policy reviews and surveys on vaccine hesitancy [4].

Results

Clinical trials consistently demonstrate that HPV vaccines are highly effective, with efficacy rates exceeding 90% against infection by targeted HPV strains and associated precancerous lesions when administered before exposure. The FUTURE II trial reported a 98% reduction in CIN2/3 among HPV-naïve women vaccinated with Gardasil, while the PATRICIA trial showed similar outcomes for Cervarix against HPV-16/18-related lesions. Long-term follow-up studies, now spanning nearly two decades, confirm sustained protection, with no significant waning of immunity [5]. In countries with robust vaccination programs, real-world impact is evident. Australia, which introduced a national HPV vaccination program in 2007, achieved over 80% coverage among girls and saw a 77% decline in HPV-16/18 prevalence and a 50% reduction in high-grade cervical abnormalities by 2020. Sweden reported a 90% decrease in cervical cancer incidence among vaccinated cohorts by 2023 [6]. Globally, the WHO estimates that HPV vaccination could prevent 4.5 million cervical cancer deaths by 2050 if 90% of girls are vaccinated by age 15. However, coverage remains uneven: high-income countries average 67% vaccination rates, while low-income countries lag at under 10%. In sub-Saharan Africa, where cervical cancer is the leading cause of cancer death among women, only 15% of eligible girls were vaccinated by 2024, largely due to cost, supply chain issues, and misinformation [7].

Discussion

The evidence is unequivocal: HPV vaccination is a cornerstone of cervical cancer prevention. Its ability to target the root cause—HPV infection—distinguishes it from secondary prevention methods like Pap smears, which detect rather than prevent disease. The vaccines’ success in reducing HPV prevalence, precancerous lesions, and cervical cancer incidence in high-coverage settings exemplifies their potential as a public health triumph. Australia’s experience, where near-elimination of vaccine-targeted HPV strains is within reach, offers a blueprint for other nations [8]. Moreover, vaccinating boys, as implemented in some countries, enhances herd immunity and reduces HPV transmission, amplifying population-level benefits. Yet, the global picture is less encouraging. Disparities in vaccine access mirror broader inequities in healthcare, with low-income regions bearing the heaviest cervical cancer burden yet the least vaccination coverage. Economic barriers, including the high cost of vaccines (up to $150 per course), deter widespread adoption in resource-poor settings, despite initiatives like Gavi, the Vaccine Alliance, which subsidizes costs. Cultural factors, including vaccine hesitancy fueled by misinformation about safety and fertility risks, further complicate uptake [9]. For instance, a 2023 survey in India found that 40% of parents distrusted the HPV vaccine due to unfounded safety concerns. Scaling up vaccination requires not only financial investment but also education campaigns and integration with existing immunization platforms, such as childhood vaccination schedules. The WHO’s 90-70-90 strategy—aiming for 90% vaccination, 70% screening, and 90% treatment access by 2030—sets an ambitious target, but current trends suggest that without accelerated action, this goal may remain elusive for much of the world [10].

Conclusion

HPV vaccination stands as one of the most effective tools for preventing cervical cancer and reducing its global incidence. Its proven efficacy, coupled with real-world declines in HPV-related outcomes in vaccinated populations, underscores its transformative potential. In high-coverage settings, the path to cervical cancer elimination is clear, offering hope that this disease could become a rarity within decades. However, the vaccine’s promise is curtailed by stark disparities in access and uptake, particularly in regions where the need is greatest. Bridging this gap demands a multifaceted approach: lowering costs through international cooperation, strengthening health infrastructure, and countering misinformation with evidence-based outreach. As of March 27, 2025, the data affirm that HPV vaccination is not merely a medical intervention but a global health imperative. Achieving its full impact will require sustained commitment to equity, ensuring that every girl—and increasingly, every boy—has the chance to be protected from a preventable cancer. Only then can the world move closer to eradicating cervical cancer as a public health threat.

References

1. Busch A, Jäger M, Mayer C, Sowislok A (2021) Functionalization of Synthetic Bone Substitutes. Int J Mol Sci 22: 4412

Indexed at, Google Scholar, Crossref

2. Jayash S, Al-Namnam NM, Shaghayegh G (2020) Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives. Biointerface Res Appl Chem 10: 5193-5200.

Google Scholar, Crossref

3. Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A (2019) Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers 11: 1332.

Indexed at, Google Scholar, Crossref

4. Menéndez S, Gallego B, Murillo D, Rodríguez A, Rodríguez R, et al. (2021) Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas. J Clin Med 10: 2621.

Indexed at, Google Scholar, Crossref

5. Rajani R, Gibbs CP (2012) Treatment of Bone Tumors. Surg Pathol Clin 5: 301-318.

Indexed at, Google Scholar, Crossref

6. Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z, et al. (2019) Advances in immune checkpoint inhibitors for bone sarcoma therapy. J Bone Oncol 15: 100221.

Indexed at, Google Scholar, Crossref

7. Ferracini R, Martínez-Herreros I, Russo A, Casalini T, Rossi F, et al. (2018) Scaffolds as Structural Tools for Bone-Targeted Drug Delivery. Pharmaceutics 10: 122.

Indexed at, Google Scholar, Crossref

8. Cortini M, Baldini N, Avnet S (2019) New Advances in the Study of Bone Tumors: A Lesson from the 3D Environment. Front Physiol 10: 814.

Indexed at, Google Scholar, Crossref

9. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.

Indexed at, Google Scholar, Crossref

10. Rosati LM, Herman JM (2017) Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients with Pancreatic Cancer. J Oncol Pract 13: 157-166.

Indexed at, Google Scholar, Crossref